Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.

Authors

• Gerard J Criner
• Frederick M Lang
• Robert L Gottlieb
• Kusum S Mathews
• Tisha S Wang
• Todd W Rice
• Deepu Madduri
• Shashi Bellam
• Robert Jeanfreau
• Amy H Case
• Marilyn K Glassberg
• George Marshall Lyon
• Kareem Ahmad
• Robert Mendelson
• J Michael DiMaio
• MaryAnn P Tran
• Cedric W Spak
• Jamil A Abbasi
• Steven G Davis
• Shekhar Ghamande
• Steven Shen
• Lisa Sherman
• Simon Lowry

Publication/Presentation Date

6-1-2022

Volume

205

Issue

11

First Page

1290

Last Page

1299

ISSN

1535-4970

Published In/Presented At

Criner, G. J., Lang, F. M., Gottlieb, R. L., Mathews, K. S., Wang, T. S., Rice, T. W., Madduri, D., Bellam, S., Jeanfreau, R., Case, A. H., Glassberg, M. K., Lyon, G. M., Ahmad, K., Mendelson, R., DiMaio, J. M., Tran, M. P., Spak, C. W., Abbasi, J. A., Davis, S. G., Ghamande, S., … Lowry, S. (2022). Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. American journal of respiratory and critical care medicine, 205(11), 1290–1299. https://doi.org/10.1164/rccm.202108-1859OC

Disciplines

Medicine and Health Sciences

PubMedID

35290169

Department(s)

Department of Medicine

Document Type

Article